Your browser is no longer supported. Please, upgrade your browser.
KZR Kezar Life Sciences, Inc. daily Stock Chart
Kezar Life Sciences, Inc.
Index- P/E- EPS (ttm)-1.05 Insider Own22.80% Shs Outstand20.97M Perf Week-15.11%
Market Cap475.81M Forward P/E- EPS next Y-2.15 Insider Trans- Shs Float15.50M Perf Month-11.81%
Income-19.70M PEG- EPS next Q-0.44 Inst Own47.50% Short Float5.32% Perf Quarter14.36%
Sales- P/S- EPS this Y5.30% Inst Trans10.14% Short Ratio13.83 Perf Half Y-
Book/sh6.02 P/B3.77 EPS next Y- ROA- Target Price29.50 Perf Year-
Cash/sh5.38 P/C4.22 EPS next 5Y- ROE- 52W Range14.77 - 36.33 Perf YTD27.83%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-36.91% Beta-
Dividend %- Quick Ratio32.90 Sales past 5Y- Gross Margin- 52W Low55.18% ATR2.88
Employees24 Current Ratio32.90 Sales Q/Q- Oper. Margin- RSI (14)41.45 Volatility17.28% 10.15%
OptionableNo Debt/Eq0.00 EPS Q/Q-163.10% Profit Margin- Rel Volume0.99 Prev Close22.69
ShortableYes LT Debt/Eq0.00 EarningsNov 08 Payout- Avg Volume59.66K Price22.92
Recom1.30 SMA20-14.71% SMA50-8.83% SMA20010.97% Volume21,820 Change1.01%
Jul-16-18Initiated William Blair Outperform
Jul-16-18Initiated Wells Fargo Outperform $30
Jul-16-18Initiated Jefferies Buy
Dec-05-18 08:00AM  Kezar Life Sciences to Present at The BMO Prescriptions for Success Healthcare Conference GlobeNewswire
Nov-26-18 02:03PM  Here's how much better insiders have profited from this year's IPO boom American City Business Journals -5.90%
Nov-08-18 08:00AM  Kezar Life Sciences Reports Third Quarter 2018 Financial Results and Provides Business Update GlobeNewswire
Nov-07-18 08:00AM  Kezar Life Sciences to Present at Jefferies 2018 London Healthcare Conference GlobeNewswire
Aug-29-18 08:00AM  Kezar Life Sciences to Present at 2018 Wells Fargo Healthcare Conference GlobeNewswire
Aug-09-18 04:05PM  Kezar Life Sciences Reports Second Quarter 2018 Financial Results and Provides Business Update GlobeNewswire
Jul-17-18 10:00AM  Former Pappas Portfolio Company CEO Retracts Anonymous Allegations PR Newswire
Jun-29-18 02:39PM  Here's how 14 Bay Area IPOs did in the strongest first half in 4 years American City Business Journals
Jun-28-18 09:07AM  Pair of upsized Bay Area biotech IPOs head in opposite directions after raising $335M American City Business Journals
Jun-25-18 04:05PM  Kezar Life Sciences Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares PR Newswire
02:37PM  The Funded: More biotech IPOs highlight Bay Area venture news this week, along with a new Jay Z VC fund American City Business Journals
Jun-21-18 11:41AM  [$$] Banner Day for Biotech as Five Drug Developers Go Public The Wall Street Journal
Jun-20-18 08:05PM  Kezar Life Sciences Announces Pricing of Initial Public Offering PR Newswire
03:11PM  8 Biotech Stocks With IPOs This Week InvestorPlace
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. Its lead product candidate, KZR-616, a selective immunoproteasome inhibitor that is in Phase 1b/2 clinical trials in lupus and lupus nephritis The company was incorporated in 2015 and is headquartered in South San Francisco, California.